




**A FITC-Echistatin binding to  $\alpha\text{IIb}\beta\text{3}$** **Figure S6. Related to Fig. 7. Influence of serum on the binding affinities of selected  $\alpha\text{IIb}\beta\text{3}$  inhibitors.**

(A) Binding affinity of  $\alpha\text{IIb}\beta\text{3}$  WT expressed on transiently transfected Expi293F integrin  $\alpha\text{5}$  and  $\alpha\text{V}$  knock-out cells for FITC-Echistatin determined by binding of 5 nM Alexa647-MBC319.4 Fab in L15 medium supplemented with varying concentrations of serum. Binding curves were fitted to Eq.3 for the binding affinity of FITC-Echistatin at different serum concentrations. Errors were standard fitting errors from nonlinear least square fits. (B-C) Competitive binding to measure the affinity of  $\alpha\text{IIb}\beta\text{3}$  inhibitors.  $\alpha\text{IIb}\beta\text{3}$  inhibitors at the indicated concentrations competed binding of FITC-Echistatin at the concentration shown on the y axis to  $\alpha\text{IIb}\beta\text{3}$  WT expressed on transiently transfected Expi293  $\alpha\text{5}$  &  $\alpha\text{V}$  KO cells. Mean fluorescence intensity (MFI) was determined by flow cytometry without washing.